Age-associated B cells in autoimmune diseases

Isobel C. Mouat1,2 · Erin Goldberg2 · Marc S. Horwitz2

Received: 15 March 2022 / Revised: 7 June 2022 / Accepted: 15 June 2022 / Published online: 7 July 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
Age-associated B cells (ABCs) are a transcriptionally and functionally unique B cell population. In addition to arising with age and following infection, ABCs are expanded during autoimmune disease, including those with systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. The exact nature of how ABCs impact disease remains unclear. Here, we review what is known regarding ABC development and distribution during diseases including systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. We discuss possible mechanisms by which ABCs could contribute to disease, including the production of cytokines and autoantibodies or stimulation of T cells. Finally, we speculate on how ABCs might act as mediators between sex, infection, and autoimmune disease, and discuss avenues for further research.

Keywords Age-associated B cell · T-bet B cell · Atypical B cell · Systemic lupus erythematosus · Multiple sclerosis

Introduction
Autoimmune disease occurs when self-tolerance mechanisms fail, and autoreactive lymphocytes and antibodies proliferate and target self-antigen. Examples of autoimmune disease can be identified in almost every organ and the resulting site and presentation of disease varies widely. The etiology of autoimmune disease is complex and incompletely understood, although there are known genetic and environmental contributors to disease. Additional insight into the mechanisms that drive autoimmunity is being revealed; however, the precise cause of disease, as well as curative treatments, remains elusive.

It is clear that B cells actively participate in pathogenicity of autoimmune disease. Particularly, the efficacy of B cell-depleting therapies, such as the anti-CD20 therapy, Rituximab, makes clear the pathogenic role of the B cell population [1–3]. Surprisingly, the success of B cell depletion therapy is not due to the elimination of autoreactive antibodies, as plasma cell numbers are maintained during treatment [4–7]. Although B cell depletion provides evidence that B cells are involved in the progression of various autoimmune diseases, the manner of their involvement is not completely clear. B cells are a highly heterogeneous population, and while the success of these therapies demonstrates that B cells contribute pathogenically, it is also known that certain B cell subsets can act in a regulatory manner and alleviate disease [8, 9].

Age-associated B cells (ABCs), a unique population of memory B cells, appear in both individuals with autoimmune disease and in vivo models of autoimmunity. ABCs, identified by expression of T-bet, CD11c, CD11b, and lack of CD21, were initially shown to increase during both aging and autoimmunity [10, 11]. It was then shown that ABCs also expand in a number of intracellular infections [12–14] and during transplant rejection [15]. ABCs are a class-switched, antigen-specific memory population that display a distinct transcriptional program from other B cell subsets [16, 17]. Single-cell RNA sequencing demonstrates that ABCs differentially express an array of genes compared to other B cell subsets, including those encoding transcription factors, cytokines, signaling molecules, and proteins related to motility and metabolism [18]. There is increasing evidence that ABCs play a role in autoimmune disease, though the mechanisms by which they promote disease are not fully elucidated. Possible mechanisms include the production of autoantibodies and inflammatory cytokines and/or the presentation of antigen to and stimulation of T cells. Understanding the role ABCs play in autoimmune disease...
may lend valuable insight into the initiation and progression of disease.

In this review, we describe what is currently known about the role of ABCs in various autoimmune diseases and models of autoimmunity. ABC differentiation, anatomic localization, and activation and responsiveness are discussed. We describe the current evidence regarding possible mechanisms of ABC contribution to autoimmune disease. Finally, we discuss how ABCs in the contexts of age, infection, and autoimmune disease might interrelate, and describe avenues for further research in defining ABC involvement in autoimmune disease.

**Frequency of ABCs is increased during autoimmunity**

In addition to expanding during aging and infection, ABCs accrue in numerous autoimmune diseases and mouse models of autoimmunity (Table 1). Here, we consider ABCs to be T-bet⁺, CD21⁻, CD11c⁺, CD11b⁺ B cells, or combinations thereof. The markers that define ABCs are not consistent in the literature and those termed atypical, double negative, and CD21⁻ B cells are likely similar populations to ABCs. Additionally, these identification strategies also have a degree of overlap with non-ABC B cell populations. For instance, a proportion of CD21⁻ cells might be transitional B cells or CD11b⁺ might include the B1 population. The current ABC classification requires refinement both to differentiate the population from non-ABC subsets and to better understand heterogeneity within the ABC population. For instance, different ABC markers might associate with variable stages of differentiation or represent plasticity or heterogeneity within the ABC sub-population. A common characteristic of the ABC population is their elevated frequency during autoimmune disease.

There are numerous examples of ABCs in the context of autoimmune disease. The peripheral blood of people with systemic lupus erythematosus (SLE) exhibits elevated proportions of ABCs compared to healthy individuals [19–23]. While ABCs account for roughly 1% of the circulating B cell population in healthy donors, ABC proportions can increase to over 5% in individuals with SLE [17]. ABC frequency correlates with disease; individuals with active SLE display increased ABCs compared to individuals with quiescent disease [19, 23]. People with multiple

| Disease or disease model | Species | Markers and references |
|--------------------------|---------|-----------------------|
| Systemic lupus erythematosus (SLE) | Human | CD19⁺CD21⁻⁺ [19]  
| | | CD19⁺T-bet⁺ [20]  
| | | CD19⁺CD11c⁺⁺T-bet⁺ [21]  
| | | CD19⁺T-bet⁺⁺CXCR5⁻⁻CD11c⁺⁺ [22]  
| | | CD27⁻⁻⁻⁺⁻CXCR5⁻⁻CD11c⁺ [23] |
| Multiple sclerosis (MS) | Human | CD19⁺⁺CD21⁻⁺⁺ [24]  
| | | CD19⁺⁺CD20⁺⁺CD11c⁺⁺CD21⁻⁻ [25]  
| | | CD19⁺⁺T-bet⁺⁺ [26] |
| Rheumatoid arthritis (RA) | Human | CD19⁺⁺⁺CD21⁻ [11]  
| | | CD19⁺⁺⁺CD27⁻⁻⁻CD21⁻⁻ [27]  
| | | CD19⁺⁺⁺CD27⁻⁻⁻⁺⁻CD21⁻⁻ [28] |
| Sjögren’s syndrome (SS) | Human | CD19⁺⁺⁺CD27⁻⁻⁻CD21⁻⁻ [11]  
| | | CD19⁺⁺⁺CD27⁻⁻⁻CD38⁻⁻⁻CD21⁻⁻ [28] |
| Axial spondyloarthritis | Human | CD19⁺⁺⁺⁺⁺CD21⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD27⁻⁻⁻⁻⁻CD21⁻⁻⁻ [28] |
| Scleroderma | Human | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD21⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [28] |
| Malarial autoimmune anemia | Human | B220⁺⁺CD11b⁺⁺T-bet⁺⁺ [29]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [28]  
| | | CD19⁺⁺⁺⁺⁺CD27⁻⁻⁻⁻⁻CD21⁻⁻⁻ [28] |
| Common variable immunodeficiency (CVID) with autoimmune complications | Human | CD19⁺⁺⁺⁺⁺CD21⁻⁻⁻ [30, 31]  
| | | CD19⁺⁺⁺⁺⁺CD38⁻⁻⁻⁻⁻CD21⁻⁻⁻ [32] |
| Crohn’s disease | Human | CD19⁺⁺⁺⁺⁺T-bet⁺⁺ [33]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| SLE—MER⁻⁻⁻⁻⁻ | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| SLE—NZBxWF1 | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| SLE—Chronic graft-versus-host disease | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| SLE—B6.SLE1.2.3 | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [11]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| SLE—Cutaneous lupus erythematosus | Humanized mouse | B220⁺⁺CD11b⁺⁺T-bet⁺⁺ [36]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [37] |
| Systemic autoimmunity—PTPN22 knock-in | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [37]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| MS—experimental autoimmune encephalomyelitis (EAE) | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [37]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| RA—Collagen-induced arthritis | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [37]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
| Experimental autoimmune hepatitis | Mouse | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺CD11b⁻⁻⁻ [37]  
| | | CD19⁺⁺⁺⁺⁺CD11c⁺⁺⁺⁺⁺B220⁺⁺⁺⁺⁺ [34] |
sclerosis (MS), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), and axial spondylarthritis display increased proportions of circulating ABCs [11, 24, 27, 28]. ABC frequency is increased in people with secondary autoimmune manifestations, including those with CVID with autoimmune diseases and autoimmune anemia during malaria [29–32]. Finally, ABC expansion can be observed in the peripheral blood of individuals with scleroderma and Crohn’s disease [11, 33], diseases that display auto-inflammatory characteristics. While there is strong correlation with ABC frequency and autoimmune disease, the verdict on causation is still out.

Given the various instances of ABC expansion in autoimmune disease, it appears that the presence of this subset could have important implications in disease. In vivo models are a critical tool for understanding the mechanistic relationship between ABCs and autoimmunity, and elevated proportions and numbers of ABCs are observed in various models (Table 1). Multiple mouse models for SLE demonstrate expanded levels of ABCs [11, 21, 34–37]. Similarly, ABCs are increased in the experimental autoimmune encephalomyelitis (EAE) model of MS [25], the collagen-induced arthritis model of RA [38], and a model for autoimmune hepatitis [39]. ABCs expand with age regardless of disease status, though autoimmune-prone mice exhibit elevated ABC proportions earlier in life compared to age-matched wild type mice [11].

While mouse models cannot fully recapitulate human disease, they can provide important insights into the mechanisms by which ABCs contribute to disease. In mouse models, samples are not limited to peripheral blood, and the constraints of the availability of donors can be circumvented. ABCs have primarily been examined in the peripheral blood of people with autoimmune diseases due to relative ease of access, though chemokine analyses and in vivo models demonstrate that ABCs display unique localization and trafficking patterns.

Anatomic distribution of ABCs

The localization of ABCs is unique from that of other B cell subsets and is dependent on disease state (Fig. 1). In non-autoimmune settings, ABCs are detected in the spleen, peripheral blood, and bone marrow, though are rare in lymph nodes and tonsils [17]. The spleen appears to act as the primary ABC reservoir following viral infection [17, 40]. The spleen appears to act as the primary ABC reservoir following viral infection [17, 40]. There is evidence that ABCs persist long-term in the marginal zone, where they are primed to initiate secondary germinal centres [41].
During ongoing inflammation, ABCs exit the spleen and circulate. The ABC frequency in the peripheral blood is elevated during both infection and autoimmunity [11, 19–21, 24, 25, 27, 28, 30, 31, 33, 40, 42]. The circulating ABCs may be migrating to the site of disease, as ABCs also increase in abundance at sites of inflammation. For instance, ABCs are found within kidney allografts of transplant recipients [15] and in the nasal tissue of individuals with rhinovirus infection [43]. During autoimmunity, ABCs also appear increased in the diseased tissue. Individuals with MS display greater proportions of ABCs in the cerebral spinal fluid than in paired peripheral blood samples [24]. Similarly, in the MS model EAE, higher numbers of ABCs are present in the central nervous system compared to naïve mice [25] and ABCs are increased in the liver during experimental autoimmune hepatitis [39]. In a humanized mouse model of cutaneous lupus erythematosus, wherein peripheral blood mononuclear cells (PBMCs) from lupus patients are engrafted into irradiated mice, ABCs are found within diseased skin lesions [36].

The pattern of chemokine receptors expressed by ABCs aligns with observations that ABCs localize to the site of disease. The inflammatory chemokine receptor CXCR3, generally absent on circulating B cells [44], displays increased expression on ABCs from those with axial spondyloarthritis [28] and MS [26], likely facilitating their migration to the site of disease [45]. Further, T-bet and CXCR3 expression on B cells is correlated in individuals with MS and in the collagen-induced arthritis (CIA) model of arthritis [46, 47]. Migration assays demonstrate that CXCR3 expression facilitates B cell migration [47], including across brain endothelial cell layers [46]; CXCR3 expression on ABCs in people with MS therefore may enhance their capacity to cross the blood–brain barrier and home to the diseased tissue. CXCR6 expression, implicated in extra lymphatic homing, is elevated on ABCs compared to total B cells in individuals with SLE [19].

In contrast to the spleen, circulation, and site of disease, ABCs appear largely absent from secondary lymphoid organs at steady state and during autoimmunity. In mice with collagen-induced arthritis, ABCs are found at low frequency in the inguinal lymph nodes [38]. ABCs display lower expression of CXCR5, a chemokine receptor that facilitates migration to lymph nodes, compared to follicular and marginal zone B cells [10]. In individuals with SLE, ABCs do not express CXCR4 [48], a chemokine receptor that facilitates extra lymphatic migration [49].

ABCs are found at various anatomical sites, though appear to preferentially localize to the spleen and site of inflammation. The differences in frequency of ABCs between the various compartments indicate that homeostasis is not maintained and is dependent on disease state. Localization is not the only respect in which ABCs are unique from other B cell populations; the differentiation and activation requirements of ABCs also demonstrate their distinctiveness.

**ABC origin and differentiation**

ABC differentiation requires a combination of innate sensor stimulation in the context of a certain cytokine milieu. ABCs are stimulated to differentiate following the engagement of toll-like receptors 7 or 9 (TLR7/9), the B cell receptor (BCR), and exposure to cytokines including IFNγ and IL-21 (Fig. 1). ABCs continuously differentiate from peripheral B cell populations, in contrast to derivation from bone marrow precursors, as evidenced by their slower reconstitution compared to the follicular and marginal zone B cell compartments following irradiation [10]. Engagement of the nucleic acid sensors TLR7 or 9 is required for ABC differentiation from peripheral B cells [50]. TLR7/9 can be stimulated by microbial infections or endogenous components, including cellular debris or chromatin. Recently, a gain-of-function variant that results in amplified TLR7 signaling has been shown to drive expansion of ABCs and result in lupus development [51]. Engagement of TLR7/9 is critical but not solely sufficient for the appearance of ABCs; subsequent IFNγ and/or IL-21 exposure is required for ABC differentiation from follicular B cells and is CD40-dependent. IL-4 negatively regulates IL-21-induced ABC differentiation, though it does not affect the IFNγ-dependent pathway [50]. Follicular helper cells are critical for the development of ABCs, likely due to their provision of cytokines and stimulation of CD40 [41, 52]. Individuals with mutations in genes which affect signaling of IL-21, CD40, or IFNγ display low proportions of ABCs in their peripheral blood, highlighting the important roles of these signaling pathways in ABC accumulation [53]. ABCs appear to be driven to accumulate by the same cytokine milieu during infection and autoimmune disease [50, 54]. BCR stimulation is an additional signal that stimulates the generation of ABCs; when BCR stimulation is coupled with TLR7/9 stimulation, the ABC response is magnified [10]. The combination of antigen and CpG/IFNγ stimulation resulted in high T-bet expression in human tonsil B cells [55]. ABC accumulation is negatively regulated by the Early Growth Response 2/3 transcription factors, and it appears that ABCs largely circumvent this tolerance checkpoint during autoimmune disease [56].

As a part of their generation ABCs class switch to IgG, primarily IgG1 (humans) or IgG2a/c (mice) [11, 42, 57]. This aligns with the critical role for T-bet, a primary marker of ABCs, in class switching to IgG2a [58, 59]. Whether this class switching occurs within or outside of a germinal center is incompletely understood. Class switching and affinity maturation can happen within or outside of the germinal center response [60–62] and B cells that persist indefinitely
can arise intra- or extra-follicularly [63]. Current evidence indicates that ABCs can arise from both within and outside of germinal centers, though likely predominantly arise extra-follicularly. Immunofluorescence staining has shown ABCs to be located both within and outside of the germinal center [16, 17, 64]. However, ABCs proceed the development of germinal centers during viral infection and fate-tracking showed ABC formation without germinal center entrance [41]. ABCs also display lower levels of somatic hypermutation compared to memory and germinal center B cells [16, 48]. The reliance of Bcl-6, a critical regulator of the germinal center reaction, on ABC development is unclear, with conflicting reports [41, 52]. It is likely that ABCs predominantly arise from within a germinal center, though their differentiation pathway may differ between contexts.

A requirement of the transcription factor T-bet, often used to define ABCs, for the appearance of ABCs is unclear. CD11c expression is not downstream of T-bet [50] and mice with a B cell-specific T-bet deletion display a significant but not complete loss of CD11c-expressing B cells [35, 38]. The CD11c+ B cells that do arise in these mice appear to be functional ABCs that display a similar phenotype to T-bet+ ABCs [65], although there is a loss of IgG2a class switching in the absence of T-bet [52]. It is clear that ABC differentiation results from a combination of signals that are unique from other B cell subsets.

### ABC activation and survival

ABCs also display unique activation and survival requirements. Unlike follicular and marginal zone B cells, ABCs do not rely on BAFF for survival [10, 66]. ABCs also do not proliferate upon CD40 stimulation, are hypo-responsive to BCR stimulation alone, and exhibit lower survival compared to follicular B cells [10, 31]. Further unlike other B cell types, ABCs respond more readily to TLR7 and TLR9 stimulation and secrete antibody in response to TLR rather than BCR activation [10, 23]. Some have proposed that ABCs may be anergic due to their lack of responsiveness to BCR and CD40 stimulation [27]; however, it is well documented that ABC stimulation by TLR7/9 agonists poses a robust response to BCR stimulation [10]. It is possible that ABCs are activated by viral particles which antagonize TLR as well as exhibit Ig specific antigens rather than single molecular structures. Another unique aspect that has lent people to believe ABCs are hypo-responsive is their requirement for antigens to be membrane bound, and lack of responsiveness to soluble antigen [67]. ABCs differ clearly from other B cell subsets in their responsiveness to activation signals. Better understanding of the signals controlling ABC activation may help to elucidate their roles in immune dysregulation.

### Mechanisms of ABC contribution to autoimmunity

ABCs have the capacity to contribute to autoimmune disease through a variety of mechanisms, including through the presentation of antigen, production of autoantibodies or cytokines, or initiation of germinal center development. These possible mechanisms of contribution are not mutually exclusive, and ABCs could contribute in multiple and different manners depending on the context.

### Autoantibodies

A likely way in which ABCs contribute to autoimmunity is through the production of autoantibodies. ABCs from individuals with SS produce antibodies specific to various self-antigens including rheumatoid factor (IgG), double stranded DNA, and lipopolysaccharide [27]. During malaria anemia, following pathogen stimulation of TLR9, ABCs are a major producer of autoantibodies responsible for the loss of erythrocytes [29]. ABCs at the site of disease produce IgG2a in a model of lupus characterized by skin lesions [36]. In a model of SLE ABCs produce more antichromatin IgG2a than non-ABC B cells, and depleting or knocking out ABCs results in a loss of antichromatin IgG and IgG2a [21, 35]. Murine splenic B cells differentiated into ABC-like cells through stimulation of lipopolysaccharide in the presence of IL-21 and TLR7 were responsible for the production of total IgG including IgG2a/b and IgG3 [21]. During SLE, higher proportions of ABCs positively correlate with levels of autoantibodies [11, 21, 23]. A murine model for SLE also highlighted the importance of TLR7 in the production of autoantibodies, as inhibition of TLR7 resulted in decreased autoantibody production [68]. While autoantibody production often contributes to autoimmune pathogenesis, it is not always required for the development of disease. In the MS disease model EAE, knocking out the ABC population does not alter the serum levels of myelin-specific IgG2a/c [40]. In addition to the production of antibodies, ABCs might also play a role in the germinal center response, which is critical for production of autoreactive B cell clones. T-bet expression in B cells is critical for the formation of spontaneous germinal centers in a model of SLE [35]. Coinciding with reduction of germinal center formation, T-bet deletion in B cells reduced the levels of kidney damage and mortality in this model [35]. It is likely that ABCs contribute in part to the development and exacerbation of autoimmune disease through the production of autoantibodies, and they may also facilitate germinal center development which result in autoreactive clones.
Cytokines

The production of cytokines is another likely mechanism by which ABCs contribute to disease. ABCs express a distinct cytokine profile from other B cells. The expression of numerous cytokines is increased on ABCs, including IFNγ, TNF, IL-17, IL-10, and IL-4, compared to other B cell subsets [10, 25, 69, 70]. While the ABC cytokine profile has primarily been characterized during aging and viral infection, there are a few studies that indicate that ABCs display a distinct profile during autoimmune disease. In individuals with Crohn’s disease, ABCs in the gut display increased expression of IFNγ and IL-6 compared to other B cells, and expression is further elevated during active disease [33]. ABCs in EAE mice display increased IL-17A compared to other B cells and ABCs in non-EAE mice [12]. It appears that ABCs also express regulatory cytokines. Splenic ABCs in EAE mice display increased expression of regulatory IL-10 [12], known to attenuate neuroinflammation [71]. ABC production of IL-10 is higher than other B cell subsets during experimental autoimmune hepatitis [39] and a T-bet expressing marginal zone B cell population expresses high levels of IL-10 during CIA [47]. Together, these findings indicate that cytokines produced by ABCs might contribute to disease in both pathogenic and protective manners.

In addition to the direct effects of cytokines, ABC cytokine production can influence the makeup of the B cell population. ABCs can reduce the proliferation of pro-B cells through TNF-mediated apoptosis [69], which is not shared by follicular B cells despite evidence of significant TNF production by these cells [72]. Follicular B cells in fact, are able to counteract the ABC-mediated apoptosis of pro-B cells through IL-10 production [69]. ABCs are therefore able to influence the total B cell population in unique cytokine-dependent ways.

How ABC cytokine production is induced and maintained during disease deserves further investigation. More research is needed to determine how the cytokine profile is changed during different phases of disease and the expression between lymphoid organs and site of disease. It is clear that ABCs are capable of substantial cytokine production that could contribute to disease in various manners.

T cell help

Activation of inflammatory T cells is another possible mechanism by which ABCs contribute to autoimmune disease. ABCs are able to form stable interactions with T cells and act as antigen-presenting cells [66]. Follicular B cells display largely even distribution throughout follicles, though ABCs more frequently localize in T cell or B/T cell border zones of the spleen [66]. Increased expression of CCR7 facilitates the migration of ABCs to the T cell zone, and ABCs display increased chemotaxis responsiveness, assessed by transwell migration assays, to the T cell zone chemokines CCL21 and CCL19 [66]. Once in the T cell zone, ABCs are able to form stable interactions with T cells and are more effective antigen presenters than follicular B cells in vivo [66]. ABCs also display elevated expression of costimulatory molecules, including CD80 and CD86, compared to follicular B cells [10, 11, 23].

There is evidence that ABCs stimulate pathogenic T cells during autoimmune disease. ABCs from autoimmune-prone mice are more efficient antigen-presenting cells than follicular B cells in vivo [66]. In Crohn’s disease, ABCs are important mediators of T cell cytokine expression; CD4+ T cells co-cultured with ABCs display increased IFNγ expression compared to those cultured with non-ABC B cells [33]. Individuals with Crohn’s disease that harbor higher frequencies of ABCs also exhibited increased Th1 infiltration into the gut compared to those with lower ABC frequencies [33]. In a model of SLE, mice without ABCs displayed reduced expression of T cell activation markers and IFNγ [35]. Conversely, CD11b+ B cells isolated from mice with experimental autoimmune hepatitis impaired the proliferation and IFNγ production of CD4+ T cells [39], highlighting that the mechanisms of ABC contribution likely vary between diseases. It is apparent that ABCs can influence and activate T cells through robust antigen presentation capabilities as shown both by in vitro and in vivo studies. Their ability to activate T cells in this manner may be important for the role of T cells in autoimmune disease.

ABCs and tolerance

The success of B cell therapies highlights the pathogenic role of B cells in disease [73], though subsets of B cells also act in a protective manner during autoimmune disease [74]. There is evidence that ABCs in certain contexts, or a subset of the ABC population, might promote tolerance. ABCs express elevated Fas compared to follicular B cells at steady state [11]. Fas, via its interaction with Fas ligand, plays a critical role in the maintenance of immune tolerance [75]. During autoimmune disease, circulating ABCs display elevated Fas expression compared to non-ABC B cells, including in people with SLE, SS, and CVID with autoimmune complications [19, 27, 31]. In alignment with these results, our group has observed that EAE results in increased expression of inhibitory receptors PD1, PDL1, and CTLA4 on ABCs [25]. Collectively, these findings indicate that autoimmunity may drive an increase in inhibitory receptor expression on ABCs.

It is not clear if the expression of inhibitory receptors, or the secretion of regulatory IL-10 as described above, allow for ABCs to contribute in a protective manner during disease. Mice without ABCs develop exacerbated EAE
disease, suggesting a protective function of ABCs [25]. During CIA, a T-bet expressing marginal zone B cell population is elevated during the remission phase of disease, compared to active disease [47]. This finding indicates that these cells may be acting in a manner to mitigate disease, though how this innate-like population relates to ABCs is unclear. Conversely, multiple SLE models support a pathogenic role for ABCs [21, 35]. It appears that ABCs have the capacity to contribute in both protective and pathogenic manners via a variety of mechanisms, depending on the disease context. Delineating between B cell populations that contribute to versus protect from disease may allow for the development of more targeted and efficacious therapies.

Discussion

How do ABCs differ between the contexts of autoimmune disease, aging, and infection?

Thus far ABCs have primarily been examined separately in the three contexts in which they have been implicated: infection, autoimmunity, and aging. However, these occurrences are often overlapping and intertwined. If the ABC population displays related transcriptional profiles and exerts similar functions in these different contexts remains largely unexplored, and there is value in additional side-by-side comparisons of the ABC population. One group has pursued a comparison of the ABC transcriptional profile in individuals with malaria versus those with HIV using single cell RNA sequencing [18]. They found that the ABCs display a heterogeneous transcriptional profile within individuals and disease groups, and that the ABC profiles of those with malaria and HIV were comparable [18]. Alternately, our group has demonstrated ABCs take on distinct phenotypes in mice infected with gammaherpesvirus 68 versus those induced for EAE [25]. In particular, gammaherpesvirus 68 infection leads to an upregulation of IFNγ, while EAE upregulates IL-17A expression on ABCs, and inhibitory receptor expression is downregulated during gammaherpesvirus 68 infection and upregulated on ABCs during EAE [25]. These results demonstrate that infection and autoimmunity can drive ABCs to take on distinct phenotypes.

In addition to phenotypic differences, there is evidence that ABCs display unique functional differences between contexts. While ABCs are required for germinal center formation in a model of SLE, they are dispensable for germinal center development following immunization with Chicken Gamma Globulin [35], highlighting the distinct functional roles of ABCs depending on context. Further studies to expand on the similarities and differences between ABCs in various contexts will be important; transcriptional characterization, deep ABC phenotyping by mass cytometry, and clonal repertoire analysis would be valuable. Comparison of the ABC population between individuals, and using mouse models, during various infections, autoimmune diseases, and over different ages, will help to elucidate the ways in which this population contributes to these different, often concurrent, circumstances.

Do ABCs contribute to the female sex bias in autoimmune disease?

There is a preponderance of females affected by autoimmune diseases, with females accounting for over 75% of those with autoimmune disease [76]. It has previously been suggested that ABCs might contribute to the observed female sex bias in autoimmunity [77]. ABCs display a female sex bias during aging, with similar proportions of ABCs during youth and adolescence, though increasing in proportion with age more so in females than males [11]. Recently, it has been reported that ABC frequency during viral infection and autoimmunity is increased in females more so than males in adolescent mice, demonstrating that the sex bias is not restricted to aging [25, 40, 48]. The preferential ABC accumulation in females may be due to the dominant role of TLR7 stimulation in their development; TLR7 is X-linked and partially escapes X-chromosome inactivation, leading to its overexpression in females [78]. This increased availability of TLR7 might foster ABC differentiation females. In support of unbalanced TLR7 expression resulting in the ABC sex bias, it was recently shown that duplication of Tlr7 in males overrides the observed female sex bias of ABCs in a model of SLE [48]. Given the strong correlation of sex biases in both autoimmune disease and ABC frequency, ABCs may be an important factor in our understanding of autoimmune etiology. Further investigation of the ABC population in males versus females during infection and disease is necessary to determine if the sex bias extends beyond frequency and results in distinct functional capacities in the ABC population between sexes.

Are ABCs mediators between viral infection and autoimmune disease?

A history of viral infection is a well-established contributing factor to autoimmune disease. Intriguingly, nearly all of the diseases in which ABCs are known to accumulate are associated with a history of Epstein-Barr virus infection, including SLE, MS, RA, and SS [79–86]. Current understanding of how Epstein-Barr virus contributes to autoimmune disease is limited, though a variety of possible mechanisms have been suggested [87]. Our group postulates that ABCs act as a mediating link between Epstein-Barr virus infection and disease. Previously, we have used a murine...
analog of Epstein-Barr virus, gammaherpesvirus 68, to demonstrate that latent infection results in more severe disease in EAE and collagen-induced arthritis [38, 88]. Recently, we demonstrated that ABCs remain elevated and continue to express TNF and IFNγ long-term during latent gammaherpesvirus 68 infection [40]. Therefore, we suggest that latent Epstein-Barr virus infection might stimulate the continued activation of the ABC population, poising them to contribute pathogenically at the onset of autoimmune disease. In support of this, we find that ABCs are required for gammaherpesvirus 68-exacerbation of EAE and collagen-induced arthritis; mice with a B cell-specific T-bet deletion do not develop the increase in disease severity with latent infection [25, 38]. Additionally, it has also been shown that hepatitis C virus infection results in ABC-like cells producing rheumatoid factor-type autoantibodies [89]. ABCs also expand in the presence of viral infections that have not been associated with autoimmune disease, such as murine CMV [57], influenza [17], HIV [16, 42], and SARS-CoV-2 [90].

An important avenue for further research is elucidating the mechanism(s) by which virus-induced ABCs might contribute to autoimmune disease. It is possible that the efficacy of B cell depletion therapies can be partially explained by their depletion of Epstein-Barr virus-infected B cells and/or the pathogenic ABC population.

How do current therapeutics impact the ABC population?

B cell depletion therapy is highly efficacious and a commonly used treatment in various autoimmune diseases [73]. Rituximab, a monoclonal antibody that binds to the B cell surface marker CD20 and targets those cells for destruction, is regularly used clinically to treat autoimmune disease [91, 92]. It is currently unknown if ABCs are effectively depleted by Rituximab. In some individuals with RA or SS, ABCs expressed higher levels of CD20 than other B cell subsets, indicating that they may indeed be effectively targeted [11, 27]. However, therapeutics which more specifically target ABCs might be of value, as CD20-expressing protective B cell types are inevitably depleted by Rituximab. Unfortunately, as of yet, a unique antigen on the surface of ABCs that might be used to target their destruction is yet to be identified. The ABC profile in people with autoimmune diseases receiving B cell depletion therapies should be characterized, both to determine if ABCs are effectively depleted and, if so, to examine their reconstitution profile. There is substantial evidence that the B cell subsets that reconstitute following B cell depletion are correlated with clinical course in both MS and RA and it has been suggested that monitoring of the reconstitution profile might allow for personalization of treatment regimens [2, 93, 94]. The reconstitution profile of ABCs, both the quantity of returning ABCs and their phenotypic and functional characteristics, and association with disease, should be investigated.

ABCs play an essential role in anti-viral immune responses and are required to eliminate certain infections. However, a consequence of their accumulation is likely the ability to contribute to autoimmune disease. The precise mechanism(s) by which ABCs function during autoimmune diseases requires additional delineation, though it is clear that the ABC population can exert various functional capacities, including the production of cytokines and autoantibodies and the stimulation of T cells. There are many features of ABC biology still to be investigated, including heterogeneity in the ABC population both within and between individuals and disease states and the relative contributions of ABCs at various anatomical locations. It is an exciting time to be studying ABCs, with many areas of ongoing intense investigations that will hopefully aid in better understanding this unique population and its role in autoimmune pathogenesis.

Acknowledgements The authors gratefully acknowledge support from the MS Society of Canada and Canadian Institutes of Health Research.

Author contributions IM, EG and MSH conceptualized the review and prepared the manuscript equally. IM constructed the figure with the assistance of BioRender.

Funding The work was funded by grants from the Multiple Sclerosis Society of Canada (MSSC), the Canadian Institutes of Health Research (CIHR) and personnel awards to both IM and EG from the University of British Columbia (UBC). The funders had no role in study or the decision to submit the work for publication.

Availability of data and material Not Applicable.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval and consent to participate Not Applicable.

Consent for publication All authors consent on publication of this review article.

References

1. Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H (2018) Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol 5(2):118–126. https://doi.org/10.5152/eurjrheum.2018.17096
2. Novi G, Bovis F, Fabbri S et al (2020) Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurol Neuroimmunol Neuroinflamm 7(5):e845. https://doi.org/10.1212/NXI.0000000000000845
3. Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2021) Rituximab for the treatment of multiple sclerosis: a review. J Neurol. https://doi.org/10.1007/s00415-020-10362-z
4. Looney RJ, Anolik JH, Campbell D et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580–2589. https://doi.org/10.1002/art.20430

5. Edwards JCW, Szczepanski L, Szechinski J et al (2004) Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581. https://doi.org/10.1056/NEJMoa032534

6. Piccio L, Naïssith RT, Trinkaus K et al (2010) Changes in B and T lymphocytes and chemokines with rituximab treatment in multiple sclerosis. Arch Neurol 67(6):707–714. https://doi.org/10.1001/archneurol.2010.99

7. de Moel EC, Derksen VFAM, Trouw LA et al (2018) In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Ann Rheum Dis 77(12):1836–1838. https://doi.org/10.1136/annrheumdis-2018-213823

8. Shen P, Roch T, Lamproupolou V et al (2014) IL-35-producing B cells are critical regulators of immunity during autoimmunity and infectious diseases. Nature 507(7492):366–370. https://doi.org/10.1038/nature13075

9. Matsumoto M, Baba A, Yokota T et al (2014) Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity 41(6):1040–1051. https://doi.org/10.1016/j.immuni.2014.10.016

10. Hao Y, O’Neill P, Naradikian MS, Scholz JL, Cancro MP (2011) A B cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118(5):1294–1304. https://doi.org/10.1182/blood-2011-01-330530

11. Rubtsov AV, Rubtsova K, Fischer A et al (2011) Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B cell population is important for the development of autoimmunity. Blood 118(5):1305–1315. https://doi.org/10.1182/blood-2011-01-331462

12. Rubtsova K, Rubtsov AV, Cancro MP, Marrack P (2015) Age-associated B cells: a T-bet dependent effector with roles in protective and pathogenic immunity. J Immunol 195(5):1933–1937. https://doi.org/10.4049/jimmunol.1501209

13. Cancro MP, Age-Associated B (2020) Cells. Annu Rev Immunol 38(1):315–340. https://doi.org/10.1146/annurev-immunol-090219-031130

14. Mouat IC, Horwitz MS (2022) Age-associated B cells in viral infections. Front Immunol. 2022;13. https://www.frontiersin.org/article/10.3389/fimmu.2022.871393

15. Liu Y, Zhou S, Qian J et al (2017) T-bet+CD11c+ B cells are reactive unresponsive CD21-/low B cells in Sjögren’s syndrome-associated lymphoproliferation. Arthritis Rheum 65(4):1085–1096. https://doi.org/10.1002/art.37828

16. Wilbrink R, Spoorenberg A, Arends S et al (2021) CD27-CD38lowCD21low B cells are increased in axial spondyloarthritis. Front Immunol 12:686273. https://doi.org/10.3389/fimmu.2021.686273

17. Rivera-Correia J, Guthmiller JJ, Vijay R et al (2017) Plasmodium DNA-mediated TLR9 activation of T-bet+ B cells contributes to autoimmune anaemia during malaria. Nat Commun 8(1):1282. https://doi.org/10.1038/s41467-017-01476-6

18. Warnatz K, Wehr T, Dräger R et al (2002) Expansion of CD19(low) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology 206(5):502–513. https://doi.org/10.1016/S0176-9837(01)00198-0

19. Rakhmanov M, Keller B, Gutenberger S et al (2009) Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci USA 106(32):13451–13456. https://doi.org/10.1073/pnas.090984106

20. López-Herrera G, Segura-Méndez NH, O’Farrill-Romanillos P et al (2019) Low percentages of regulatory T cells in common variable immunodeficiency (CVID) patients with autoimmune diseases and its association with increased numbers of CD4+CD45RO+ T and CD21low B cells. Allergol Immunopathol (Madr) 47(5):457–466. https://doi.org/10.1016/j.allerj.2019.01.003

21. Wang Z, Wang Z, Wang J, Diao Y, Qian X, Zhu N (2016) B-cell expressing B cells are positively associated with Crohn’s disease activity and support Th1 inflammation. DNA Cell Biol 35(10):628–635. https://doi.org/10.1089/dna.2016.3304

22. Rubtsov AV, Rubtsova K, Kappler JW, Marrack P (2013) TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice. Immunol Res 55(1–3):210–216. https://doi.org/10.1007/s12026-012-8365-8

23. Rubtsova K, Rubtsov AV, Thurman JM, Mennonna JM, Kappler JW, Marrack P (2017) B cells expressing the transcription factor
T-bet drive lupus-like autoimmunity. J Clin Invest 127(4):1392–1404. https://doi.org/10.1172/JCI91250

36. Zhou S, Li Q, Zhou S et al (2021) A novel humanized cutaneous lupus erythematosus mouse model mediated by IL-21-induced age-associated B cells. J Autoimmun 123:102686. https://doi.org/10.1016/j.jaut.2021.102686

37. Dai X, James RG, Habib T et al (2013) A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 123(5):2024–2036. https://doi.org/10.1172/JCI66963

38. Mouat IC, Morse ZJ, Shanina I, Brown KL, Horwitz MS (2021) T-bet dependent B cell differentiation in T follicular helper cells outside of germinal centers. Social Science Research Network, Rochester. https://doi.org/10.2139/ssrn.3825161

39. Liu X, Jiang X, Liu R et al (2015) B cells expressing CD11b in infection. Cell Rep 30(2):351-366.e7. https://doi.org/10.1016/j.celrep.2019.12.027

40. Mouat IC, Shanina I, Horwitz MS. Age-associated B cells are long-lasting effectors that restrain reactivation of latent γHV68. April 2022:2021.12.29.474434. https://doi.org/10.1101/2021.12.29.474434.

41. Song W, Antao OQ, Condilli E et al (2021) Development of Tbet and CD11c-expressing B cells in a viral infection requires T follicular helper cells outside of germinal centers. Social Science Research Network, Rochester. https://doi.org/10.2139/ssrn.3825161

42. Knox JJ, Buggert M, Kardava L et al (2017) T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight. https://doi.org/10.1172/jcisi.92943

43. Eccles JD, Turner RB, Kirk NA et al (2020) Tbet+ memory B cells link to local cross-reactive IgG upon human rhinovirus infection. Cell Rep 30(2):351-366.e7. https://doi.org/10.1016/j.celrep.2019.12.027

44. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM (2000) The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B cell chronic lymphocytic leukemia. Blood 95(2):627–632

45. Sørensen TL, Trebst C, Kvisiakk P et al (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 127(1–2):59–68. https://doi.org/10.1016/s0165-5728(02)00097-8

46. van Langelaar J, Rijvers L, Janssen M et al (2019) Induction of functional murine CD11c+ T-bet+B cells in malaria. Front Immunol 10:852. https://doi.org/10.3389/fimmu.2019.00852

47. Huber K, Sármay G, Kövesdi D (2016) MZ B cells migrate in a T-bet drive lupus-like autoimmunity. J Clin Invest 127(4):1392–1404. https://doi.org/10.1172/JCI91250

48. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR (2015) B cells expressing CD11b in infection. Cell Rep 30(2):351-366.e7. https://doi.org/10.1016/j.celrep.2019.12.027

49. Naradikian MS, Myles A, Beiting DP et al (2016) Cutting edge: T-bet+B cells require IL-21 and IFN-γ from type I T follicular helper cells and intrinsic Bcl-6 expression but develop normally in the absence of T-bet. J Immunol 205(4):1050–1058. https://doi.org/10.4049/jimmunol.2002006

50. Keller B, Strohmeier V, Harder I et al (2021) The expansion of T-bet+B cells in a viral infection requires T follicular helper cells outside of germinal centers. Social Science Research Network, Rochester. https://doi.org/10.2139/ssrn.3825161

51. Brown GJ, Cañete PF, Wang H et al (2022) TLR7 gain-of-function genetic variation causes human lupus. Nature. https://doi.org/10.1038/s41586-022-04642-z

52. Levack RC, Newell KL, Popescu M, Cabrera-Martinez B, Win- slow GM (2020) CD11c+ T-bet+B cells require IL-21 and IFN-γ from type I T follicular helper cells and intrinsic Bcl-6 expression but develop normally in the absence of T-bet. J Immunol 205(4):1050–1058. https://doi.org/10.4049/jimmunol.2002006

53. Kessler B, Strohmeier V, Harder I et al (2021) The expansion of human T-bet+B cells is T cell dependent. Sci Immunol. 6(64):eabhl0891. https://doi.org/10.1126/sciimmunol.6abhl0891

54. Wang S, Wang J, Kumar V et al (2018) IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c+ T-bet+B cells in SLE. Nat Commun 9(1):1758. https://doi.org/10.1038/s41467-018-03750-7

55. Ambegaokar AA, Nagata S, Pierce SK, Sohn H (2019) The differentiation in vitro of human tonsil B cells with the phenotypic and functional characteristics of T-bet+ atypical memory B cells in malaria. Front Immunol 10:852. https://doi.org/10.3389/fimmu.2019.00852

56. Masle-Farquhar E, Peters TJJ, Miosge LA et al (2022) Uncon- trolled CD21low age-associated and B1 B cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. Cell Rep 38(3):110259. https://doi.org/10.1016/j.celrep.2021.110259

57. Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P (2013) T-box transcription factor T-bet, a key player in a unique type of B cell activation essential for effective viral clearance. PNAS 110(34):E3216–E3224. https://doi.org/10.1073/pnas.1312348110

58. Peng SL, Szabo SJ, Glümer LH (2002) T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 99(8):5545–5550. https://doi.org/10.1073/pnas.082114899

59. Gerth AJ, Lin L, Peng SL (2003) T-bet regulates T-independent IgG2a class switching. Int Immunol 15(8):937–944. https://doi.org/10.1093/immunol/dxt093

60. Toellner KM, Jenkinson WE, Taylor DR et al (2021) Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers. J Exp Med 195(1):71–79. https://doi.org/10.4049/jimmunol.1500055

61. William J, Euler C, Christensen S, Shlomchik MJ (2002) Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297(5589):2066–2070. https://doi.org/10.1126/science.1073924

62. Roco JA, Mesin L, Binder SC et al (2019) Class-switch recombination occurs infrequently in germinal centers. Immunity 51(2):337-350.e7. https://doi.org/10.1016/j.immuni.2019.07.001

63. Viant C, Wirthmiller T, ElTanbouly MA et al (2021) Germinal center-dependent and -independent memory B cells produced throughout the immune response. J Exp Med 218(8):e20202489. https://doi.org/10.1084/jem.20011112

64. Ambegaokar AA, Kwak K, Sohn H, Manzella-Lapeira J, Brzos- towski J, Pierce SK (2020) Expression of inhibitory receptors by B cells in chronic human infectious diseases restricts responses to membrane-associated antigens. Sci Adv 6(30):eaab6493. https://doi.org/10.1126/sciadv.aba4693

65. Murakami Y, Fukui R, Tanaka R, et al. Anti-TLR7 antibody pro- tects against lupus nephritis in NZBWF1 mice by targeting B

© Springer
cells and patrolling monocytes. Front Immunol. 2021;12. https://www.frontiersin.org/article/https://doi.org/10.3389/fimmu.2021.777197. Accessed 6 Feb 2022.

69. Ratliff M, Alter S, Frasca D, Blomberg BB, Riley RL (2013) In senescence, age-associated B cells secrete TNFα and inhibit survival of B cell precursors*. Aging Cell 12(2):303–311. https://doi.org/10.1111/ace.12055

70. Frasca D, Romero M, Garcia D, Diaz A, Blomberg BB (2021) Hyper-metabolic B cells in the spleens of old mice make antibodies with autoimmune specificities. Immun Age 18(1):9. https://doi.org/10.1861/s12979-021-00222-3

71. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3(10):944–950. https://doi.org/10.1038/ni833

72. Frasca D, Romero M, Diaz A et al (2012) A molecular mechanism for TNF-α-mediated downregulation of B cell responses. J Immunol 188(1):279–286. https://doi.org/10.4049/jimmunol.1003964

73. Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Dis 20(3):179–199. https://doi.org/10.1038/s41573-020-0092-2

74. Hofmann K, Clauder AK, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835. https://doi.org/10.3389/fimmu.2018.00835

75. Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N (2017) Dual role of Fas/FasL-Mediated signal in peripheral immune tolerance. Front Immunol 8:403. https://doi.org/10.3389/fimmu.2017.00403

76. Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epide- miology and estimated population burden of selected autoim- mune diseases in the United States. Clin Immunol Immunopathol 84(3):223–243, https://doi.org/10.1006/ciim.1997.4411

77. Rubtsova K, Marrack P, Rubtsov AV (2012) Age-associated B cells: are they the key to understanding why autoimmune diseases are more prevalent in women? Expert Rev Clin Immunol 8(1):5–7. https://doi.org/10.1586/eci.11.83

78. Souyris M, Cenac C, Azar P et al (2018) TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol 3(19):eaap8855. https://doi.org/10.1126/sciimmunol.aap8855

79. Moon UY, Park SJ, Oh ST et al (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 6(4):R295-302. https://doi.org/10.1186/1475-9916-6-302

80. Draborg AH, Jacobsen S, Westergaard M et al (2014) Reduced virus load in synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 67(4):1134–1140

81. Thacker EL, Mirzaei F, Ascherio A (2006) Infectious mononucleosis and risk for multiple sclerosis. Ann Neurol 59(3):499–503. https://doi.org/10.1002/ana.20820

82. Bjornevik K, Cortese M, Healy BC et al (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375(6578):296–301. https://doi.org/10.1126/science.abj8222

83. Balandraud N, Meynard JB, Auger I et al (2003) Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 48(5):1223–1228. https://doi.org/10.1002/art.10933

84. Croia C, Serafini B, Bombardieri M et al (2013) Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis 72(9):1559–1568. https://doi.org/10.1136/annrheumdis-2012-202352

85. Alspaugh MA, Henle G, Lennette ET, Henle W (1981) Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest 67(4):1134–1140

86. Inoue H, Mishima K, Yamamoto-Yoshida S et al (2012) Aaryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjögren’s syndrome. J Immunol 188(9):4654–4662. https://doi.org/10.4049/jimmunol.1101575

87. Bar-O, Pender MP, Khanna R et al (2020) Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med 26(3):296–310. https://doi.org/10.1016/j.tomolmed.2019.11.003

88. Casiraghi C, Shanaia I, Cho S, Freeman ML, Blackman MA, Horwitz MS (2012) Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis. PLoS Pathog 8(5):e1002715. https://doi.org/10.1371/journal.ppat.1002715

89. Comarmond C, Lorin V, Marques C et al (2019) TLR9 signaling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. J Hepatol 71(S):908–919. https://doi.org/10.1016/j.jhep.2019.06.029

90. Woodruff MC, Ramonell RP, Nguyen DC et al (2020) Extrafol- licular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol 21(12):1506–1516. https://doi.org/10.1038/s41590-020-00814-z

91. Gürcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9(1):10–25. https://doi.org/10.1016/j.intimp.2008.10.004

92. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47):7359–7368. https://doi.org/10.1038/sj.onc.1206939

93. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54(2):613–620. https://doi.org/10.1002/art.21617

94. Li R, Patterson KR, Bar-O A (2018) Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19(7):696–707. https://doi.org/10.1038/s41590-018-0135-x